{"organizations": [], "uuid": "d4c8400e3784ac59ede7509292ccc1255d586606", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/24/globe-newswire-nasdaq-welcomes-kiniksa-pharmaceuticals-ltd-nasdaqknsa-to-the-nasdaq-stock-market.html", "country": "US", "domain_rank": 767, "title": "Nasdaq Welcomes Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) to The Nasdaq Stock Market", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.013, "site_type": "news", "published": "2018-05-25T02:51:00.000+03:00", "replies_count": 0, "uuid": "d4c8400e3784ac59ede7509292ccc1255d586606"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/24/globe-newswire-nasdaq-welcomes-kiniksa-pharmaceuticals-ltd-nasdaqknsa-to-the-nasdaq-stock-market.html", "ord_in_thread": 0, "title": "Nasdaq Welcomes Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) to The Nasdaq Stock Market", "locations": [], "entities": {"persons": [{"name": "kiniksa", "sentiment": "none"}], "locations": [{"name": "new york", "sentiment": "none"}, {"name": "times square", "sentiment": "none"}], "organizations": [{"name": "nasdaq welcomes kiniksa pharmaceuticals, ltd.", "sentiment": "neutral"}, {"name": "kiniksa pharmaceuticals, ltd.", "sentiment": "neutral"}, {"name": "nasdaq marketsite", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA), a clinical-stage biopharmaceutical company, visited the Nasdaq MarketSite in Times Square today for its initial public offering (IPO) on The Nasdaq Stock Market.\nKiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).\nKiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with unmet medical need. Formed less than three years ago, the company has rapidly built a pipeline of five product candidates across various stages of development, currently focused on autoinflammatory and autoimmune diseases.\n“As it works to develop life-changing therapies for debilitating diseases, Kiniksa Pharmaceuticals represents the kind of ambitious, forward-thinking growth company that embodies the Nasdaq spirit,” said Nelson Griggs, President, Nasdaq Stock Exchange. “We look forward to supporting Kiniksa as it pursues its vision of becoming an industry leader and a fully integrated global pharmaceutical company.”\nThe information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.\nAbout Nasdaq\nNasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: http://business.nasdaq.com\nMedia Relations Contact:\nEmily Pan\n(646) 441-5120\nemily.pan@nasdaq.com\n- NDAQG -\nA photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b43c882e-d9f7-4e8a-9fdb-e09bdf307629\nSource:Nasdaq, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=iWsH7Y0zwix_u5HQM2vD-pBNh7XMj6Hzhoe8AmGAe1OmWm2hI-PBglH_uggITlV4yfU7hGGTAi-wQIVMSOzRt2ccIZKvrJsk4wndO_eGxd0=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/3f609fd4-125d-41d9-a34b-442931f59c0e", "https://www.globenewswire.com/Tracker?data=2OE7l2KZ4aSTpX9gAPt1gIqYTxH8t8eWKw6lB5eL303f3LgMj19N-ty9HI5wSjHZ", "https://www.globenewswire.com/NewsRoom/AttachmentNg/b43c882e-d9f7-4e8a-9fdb-e09bdf307629/en", "https://www.globenewswire.com/Tracker?data=iWsH7Y0zwix_u5HQM2vD-iNwZLN1_peyUesCQnjhPeSjUogD3_PZRTrC-elnOWVL3DLsgEzKM_t5dssSH9UJECd2Up_r0mqgqKvT5mNCGH7RgPytG6BA42gg9m5Cw4rSKEZwHuv4fNgrQxQ_vky4IyQoDvWsvzRgEY5GmczObVh2zJ7aE6EpJtGcEwDtHzoLm_-Ge4g6mRegM6QmpY_ENsOPA03MUts7fqc9K2KJZ25eL9SWsaaJY-vkvpTF9v-lVNdHWJS-4bKuu6Jt4JNQ2Q==", "https://www.globenewswire.com/Tracker?data=W9FpJKu9mlkWuyJrB2aVpfwfqqhW7MQU-NmceRgWsQdzE_rDmW4bzGV-ouDhAtX6D66oB9ZFdcKvt5Od8JXIYZCpuVlJGcQrMe2fOCzrKTw=", "http://www.globenewswire.com/NewsRoom/AttachmentNg/b43c882e-d9f7-4e8a-9fdb-e09bdf307629"], "published": "2018-05-25T02:51:00.000+03:00", "crawled": "2018-05-25T02:59:05.000+03:00", "highlightTitle": ""}